References

Hampson, A.J., et al. 1998. Cannabidiol and tetrahydrocannabinol are neuroprotective antioxidants. Proceedings of the National Academy of Sciences 95(July 7):8268.

De Petrocellis L (1998) Proceedings of the National Academy of Sciences 95(July 7):

Caligano A (1998) Nature 16-7-98

Ammenheuser M (et al) 1998 Mutation Research 1998;403:55-64.

Solowij N (1998) Cannabis and Cognitive Functioning. Cambridge University Press

Atha M J (1987) Quantitative Assessment of Illicit Substance Use. (Unpublished MSc Thesis) University of Birmingham

Atha M.J.& Blanchard S (1986) Cannabis use in Britain - appendix in: Henman A, Malyon T & Lewis R (1986) Big Deal - The politics of the illicit drugs business. London: pluto Press (brief summary of results from 1982 pilot study & 1984)

Atha MJ & Blanchard S (1997) Regular Users - Self-reported drug consumption patterns and attitudes to drugs among 1333 regular cannabis users. Independent Drug Monitoring Unit

McBride AJ (1995) Cannabis use in a drug and alcohol clinic population. Drug & Alcohol Dependence 39 pp29-32

Schaeffer J. Andrysiak T. & Ungerleider J.T. (1981) Cognition & long-term use of Ganja. Science 213 pp465-466

Fairbairn JW. Hindmarch I, Simic S & Tylden E (1974) Cannabinoid content of some English reefers. Nature 249 pp276-278

Caplin S & Woodward S (1986). Drugwatch - Just Say No! London: Corgi

Atha (1987) op cit.

McBride AJ (1995) Cannabis use in a drug and alcohol clinic population. Drug & Alcohol Dependence 39 pp29-32

Atha, Blanchard & Davis 1998 - written evidence to Lords Science & Technology Committee - in preparation

Schaeffer J. Andrysiak T. & Ungerleider J.T. (1981) Cognition & long-term use of Ganja. Science 213 pp465-466

Carter W.E. & Doughty P.L. (1976) Social & Cultural aspects of cannabis use in Costa Rica. Annals of thre New York Academy of Sciences 282 pp2-16

Rubin V & Comitas L (1975) Ganja in Jamaica: a medical and anthropological study of chronic marijuana use. Den Haag: Mouton

Bowman M. Pihl R.O. (1972) Cannabis: Psychological aspects of chronic heavy use Psychopharmacology 29 pp159-170

Beaubrun M.I. (1983) Jamaica: Contrasting patterns of cannabis use. in Edwards G. Arif A & Jaffe J (Eds) Drug Use & Misuse London: Croon Helm

Stephanis C, Dornbush R & Fink M (1977) Hashish - Studies of Long Term Use Raven Press

Humphries I.J. & Joyce J.R.(1982) A survey of the cannabis content of unsmoked reefer cigarettes. Journal of the Forensic Science Society 22 pp291-292

Home Office Forensic Science Laboratory data: Results of analyses of cannabis content of "Reefer" cigarettes. Supplied by Dr Alan Patterson, Euxton, Chorley, in the course of R -v- Howes [1991]

(a) Chepstow Laboratory (b) Metropolitan Laboratory

(c) Northern Ireland Laboratory (d) Chorley Laboratory

Fairbairn JW. Hindmarch I, Simic S & Tylden E (1974). Cannabinoid content of some English reefers. Nature 249 pp276-278

Atha MJ & Blanchard S (1997) op cit. .

Atha MJ & Blanchard S (1997) - unpublished data - Novel analysis of survey data - table may be produced on request.

Anon [1971] Supermother"s Cooking with Grass. Reprinted in Cannabis Underground Library - Ronin Publishing, Berkeley Ca. Recipes call for amounts from 1/2 "lid" (approx. oz) to 1/4 cup (2oz) of "grass".

Brooke Bond PG Tips - 500g box contains 160 tea bags (3.125g per tea bag)

Atha M J (1987) op cit. .

Atha MJ & Blanchard S (1997) Regular Users op cit.

British Medical Association (1997) Therapeutic Uses of Cannabis. Harwood

Atha (1987) op cit. Atha MJ & Blanchard S (1997) op cit.

Fairbairn JW & Pickens JT (1981) British Journal of Pharmacology No 72 p401

Gieringer D (1996) Marijuana Water Pipe and Vaporiser Study MAPS Newsletter Vol. 6 No 3

Noyes et al [1975] op cit.

Milstein et al [1975] op cit.

Wheeler L [1968} op cit.

Mechoulam R. (1986) op cit.

Mott J & Mirlees Black (1995) Self-reported drug misuse in England and Wales: Findings from the 1992 British Crime Survey. London: Home Office research paper 89.

Ramsay M & Spiller J (1997) Drug Misuse Declared in 1996: latest results from the British Crime Survey. London: Home Office research paper 172

Cohen P & Sas A (1996) op cit.

Tanda G, Pontieri FE & DiChiara G (1997) Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common µ-opioid receptor mechanism.

Science 276 pp2048-2050.

de Fonseca FR, Carrera MRA, Navarro M, Koob GF & Weiss F (1997) Activation of corticotropin releasing factor in the limbic system during cannabinoid withdrawal Science 276 pp2050-2054.

Fairbairn JW & Pickens JT (1981) British Journal of Pharmacology No 72 p401

Zuarte AW, Shirakawa I, Finkelfarb E & Karniol IG (1982) Psychopharmacology No 76 p245

Mechoulam R, Srebnik M & Burstein S (1985) Marijuana 84 - The Proceedings of the Oxford Symposium on Cannabis p6 IRL Press

Young F.L (1988) In the Matter of Marijuana Rescheduling Petition: Opinion and recommended ruling, findings of fact, conclusions of law and decision of administrative law judge. U.S. Department of Justice - Drug Enforcement Administration. Docket No. 86-22 (6-9-88)

World Health Organisation: Expert Committee on Drug Dependence. 27th Report 1991

Pertwee RG (1993) The evidence for the existence of cannabinoid receptors. Gen. Pharmacol 24 pp811-824

Culpepper N (1616-1654) Culpepper"s Complete Herbal. London: Foulsham

Rubin V (1976) Cannabis and Culture. Den Haag: Mouton pp70-73

O"Shaughnessy WB (1837) On the preparation of Indian Hemp, or Gunja. Transactions of the Medical & Physical Society of Bengal 1838-1840 pp421-461 (reproduced in Mikuriya TH (Ed) (1973) Marijuana Medical Papers 1839-1972. Oakland Ca: Medi-Comp Press).

Mattison JB [1891] Cannabis Indica as an Anodyne and Hypnotic. St Louis Medical & Surgical Journal 61 pp265-271

Reynolds JR [1890] Therapeutical Uses and Toxic Effects of Cannabis Indica. Lancet. 1 637-638

Mikuriya TH [1973] Marijuana Medical Papers. Berkeley: Medi-Comp Press

Wheeler LM [1968] Department of Product Development, Parke-Davis & Co, Detroit, Michigan. Correspondence to the editor in Mikuriya (ed) [1973] op cit.

Mechoulam R. (1986) Cannabinoids as Therapeutic Agents. Boca Raton Fla. CRC Press pp108-120

Welch SP & Stevens DL (1992) Antinociceptive activity of intrathecally administered cannabinoids, alone and in combination with morphine, in mice. J Pharmacol Exper Ther 262 pp10-18.

Lichtman AH & Martin BR (1991) Spinal and supraspinal components of cannabinoid-induced antinociception. J Pharmacol Exper Ther 258 pp517-523.

Martin WJ et al (1993) Antinociceptive actions of cannabinoids following intraventricular administration in rats. Brain Research 629 pp300-304.

Mechoulam R. (1980) Current Status of Therapeutic Opportunities based on Cannabinoid Research - An Overview. Journal of Clinical Pharmacology 21 pp2-7

Noyes R, Brunk SF, Baram DA & Canter A [1975] Analgesic effect of Delta-9-tetrahydrocannabinol. Journal of Clinical Pharmacology 15 (2,3) pp139-143

Noyes R, Brunk SF, Avery DH & Canter A [1975] The analgesic properties of Delta-9-tetrahydrocannabinol and codeine. Clinical Pharmacology & Therapeutics 18 (1) pp84-89

Milstein SL, MacCannell K, Karr G & Clark S [1975] Marijuana-produced changes in pain tolerance - experienced and non-experienced subjects. International Pharmacopsychiatry 10 pp177-182

Young FL (1988) op cit.

Ungerleider JT, Andrysiak RN, Fairbanks L, Ellison GW, & Myers LW [1988] Delta-9 THC in the treatment of spasticity associated with Multiple Sclerosis. Pharmacological Issues in Alcohol & Substance Abuse pp39-50

Pertwee RG (1995) Pharmacological, physiological and other clinical implications for the discovery of cannabinoid receptors: an overview. In Pertwee RG (Ed) Cannabis Receptors. London: Academic Press. pp1-34

Petro DJ & Ellenberger C. (1981) Treatment of human spasticity with D9 tetrahydrocannabinol. J Clin Pharmacol. (Suppl) 21 pp413s-416s.

Meinck H-M et al (1989) Effect of cannabinoids on spasticity and ataxia in multiple sclerosis.

J. Neurol 236 pp120-122

Maurer M et al (1990) Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial. Eur Arch Psychiatry Clin Neurosci. 240 pp1-4

El-Mallakh RS [1987] Marijuana and Migraine. Headache Journal 27(8) pp442-443

Atha & Blanchard [1996] op cit.

O'Shaughnessy WB [1839] On the preparations of Indian Hemp, or Gunja. Transactions of the Physical and Medical Society of Bengal 1838-40 pp421-461 Reprinted in Mikuriya TH (Ed) [1973] Marijuana Medical Papers 1839-1972 Berkeley: Medi Comp Press

McMeens RR [1860] Report of the Ohio State Medical Committee on Cannabis Indica Reprinted in Mikuriya TH (Ed) [1973] op cit.

Reynolds JR [1890] Therapeutical Uses and Toxic Effects of Cannabis Indica. Lancet 1 pp637-638

Davis JP & Ramsey HH [1949] Anti-epileptic action of marijuana-active substances. Fed Proc Am Soc Exp Biol 8 pp284 Reprinted in Mikuriya TH (Ed) [1973] op cit.

Loewe S [1950] The active principles of cannabis and the pharmacology of the cannabinoids Arch Exper Path u Pharmakol 211 pp175-193 (Ger: Translation in Mikuriya TH (Ed) [1973] op cit.

Consroe PF, Jones B, Laird H, Reinking J [1976] Anticonvulsant-convulsant effects of delta-9-tetrahydrocannabinol. Ch. in Cohen & Stillman (Eds) The Therapeutic Potential of Marijuana. Plenum Press: New York pp363-382

Consroe PF et al [1975] Anticonvulsant nature of marijuana smoking JAMA 234 pp306-307

Consroe PF & Fish BS [1981] Rabbit behavioural model of marijuana psychoactivity in humans Medical Hypotheses 7 pp1079-1090

Cunha JM et al [1980] Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 21 pp175-185

Karler R & Turkanis SA [1976] The antiepileptic potential of the cannabinoids. Ch. in Cohen & Stillman (Eds) The Therapeutic Potential of Marijuana. Plenum Press: New York pp383-396

Karler R & Turkanis SA [1978] Cannabis and Epilepsy Ch. in Nahas G & Paton WDM (Eds) Marijuana Biological Effects Oxford: Pergamon Press

Ng SKC, Brust JCM, Hauser WA, Susser M [1990] Illicit drug use and the risk of new-onset seizures. Amer J Epidemiology 132(1) pp47-57

Feeney DM, Spiker M & Weiss GK [1976] Marijuana and epilepsy: Activation of symptoms by delta-9-THC Ch. in Cohen & Stillman (Eds) op cit. pp343-362

Feeney D [1976] Marijuana use among epileptics JAMA 235 p1105

Feeney DM [1978] Marijuana and epilepsy: Paradoxical anticonvulsant and convulsant effects Ch. in Nahas G & Paton WDM (Eds) Marijuana Biological Effects Oxford: Pergamon Press

Keeler MH & Riefler CB [1967] Grand Mal Convulsions subsequent to Marijuana use Dis Nerv Syst 28 pp474-475

Perez Reyes M & Wingfield M [1974] Cannabidiol and electroencephalographic epileptic activity. JAMA 230 (12) p1635

Allentuck S [1944] Medical Aspects Ch. in Cattell J [1944] The Marijuana Problem in the City of New York NY: Ronald Press Reprinted in Mikuriya TH (Ed) [1973] op cit.

Grinspoon L & Bakalar JB [1993] Marijuana: Forbidden Medicine Yale University Press

Tanda G, Pontieri FE & Di Chiara G (1997) Cannabinoid and heroin activation of the mesolimbic dopamine transmission of a common µ1 opioid receptor mechanism. Science 276 pp2048-2050

de Fonseca FR, Carrera MRA, Navarro M, Koob G & Weiss F (1997) Activation of the corticotropin releasing factor in the limbic system during cannabinoid withdrawal. Science 276 pp2050-2054

Laurie P (1967) Drugs: Medical, psychological and social facts. London: Penguin

Rosenthal E, Mikuriya TH & Gieringer D (1997) Marijuana Medical Handbook. Oakland: Quick American Archives ibid. p 58

ibid. p61

Bello J (1997) The benefits of marijuana physical, psychological and spiritual.

Cottonwood CA; Sweetlight Books

Weil A (1972) The Natural Mind Boston: Houghton Mifflin p76

Thompson LJ & Proctor RC (1953) Pyrahexyl in the treatment of drug and alcoholic withdrawal conditions. North Carolina Medical Journal 14 p321 - Cited Grinspoon L (1977) Marijuana Reconsidered. Harvard University Press

Adams R (1942) Marijuana Harvey Lectures 36 pp168-197 - Cited Grinspoon L (1977) Marijuana Reconsidered. Harvard University Press

Williams EG et al (1946) Studies on Marijuana and Pyrahexyl compound. Public Health Reports 61 pp1064-1074 - Cited Grinspoon L (1977) Marijuana Reconsidered. Harvard University Press

Davies BH, Weatherstone RM, & Graham JDP (1974) A pilot study of orally administered delta nine trans THC in the management of patients undergoing radiotherapy for carcinoma of the bronchus. British Journal of Clinical Pharmacology 1 pp301-306

Gregg JM, Small EW, & Moore R (1976) Emotional response to intravenous delta-9-tetrahydrocannabinol during oral surgery. Journal of Oral & Maxillofacial Surgery 34(4) pp301-313

Mechoulam R & Carlini EA (1978) Naturwissenschaften 65(4) pp174-179

Musty RE (1984) Possible anxiolytic effects of cannabidiol. in Agurell S, Dewey WL & Willette RE (Eds) The Cannabinoids: Chemical, Pharmacologic and Therapeutic Aspects. Academic Press.

Benowitz NL & Jones RT (1977) Clin Pharmacol Ther. 21 p336, cited Mechoulam (1978) op cit.

Fabre LF & McLendon D (1981) The efficacy and safety of Nabilone (a synthetic cannabinoid) in the treatment of anxiety. Journal of Clinical Pharmacology 21 (cannabinoids supplement) pp 377S-382S

Nakano S, Gillespie HK, & Hollister LE (1978) A model for evaluation of antianxiety drugs with the use of experimentally induced stress: Comparison of nabilone and diazepam. Clinical Pharmacology & Therapeutics 23(1) pp54-62

Hollister LE (1984) THC as a sedative, hypnotic and muscle relaxant. Ch. in Harvey DJ, Paton W & Nahas GG (1984 Eds) Marijuana 84 - proceedings of the Oxford symposium on cannabis. Oxford: IRL

Glass RM, Uhlenhuth EH, Hartel FW, Schuster CR & Fischman MW (1981) Journl of Clinical Pharmacology 21 (383S-396S) - cited Hollister (1984) op cit.

Moreau-de-Tours JJ (1845) Lypemanie aver stupeur; tendence a la demence, traitement par l'extrait (principe resineux) de cannabis indica -Guerison. Lancette Gazette Hopital 30 p391 (cited Grinspoon & Bakalar 1993)

Stockings GT (1947) A new euphoriant for depressive mental states. British Medical Journal 1 pp918-922

Bolls EJ & Stafford-Clark D (1954) Depersonalisation treated by Cannabis Indica and Psychotherapy. Guys Hospital Reports 103 pp330-336

Kotin J. Post RM & Goodwin FK (1973) Delta-9-tetrahydrocannabinol in depressed patients. Arch Gen Psychiat 28 pp345-348 - cited Grinspoon L (1977) op cit.

Regelson , Butler JR, Schulz J, Kirk T, Peek L, Green ML & Zalis MO (1976) D9 Tetrahydrocannabinol as an effective antidepressant and appetite stimulating agent in advanced cancer patients. Ch. in Braude M & Szara S (Eds) The Pharmacology of Marijuana New York: Raven Press

Grinspoon L & Bakalar JB (1993) Marijuana - the forbidden medicine. Yale University Press

Rumphius herbarium Amboinense Vol 5 ch 35 p208 (1695) Cited in Mikuriya TH (1973) op cit.

Cited in Mikuriya TH (1973) op cit. pp127-128

Cited in Mikuriya TH (1973) op cit. pp148

Cited in Mikuriya TH (1973) op cit. pp154

Vachon L, Mikus P, Morrissey W, Fitzgerald M & Gaensler E (1976). Bronchial effect of Marijuana Smoke in Asthma. Ch. in Braude M & Szara S (Eds) Pharmacology of Marijuana Vol 2. New York: Raven Press

Tashkin DP, Shapiro B, & Frank IM (1976) Acute effects of marihuana on airway dynamics in spontaneous and experimentally induced bronchial asthma. Ch. in Braude M & Szara S (Eds) op cit.

Tashkin DP, Reiss S, Shapiro BJ, Calvarese B Olsen JL & Lodge JW (1977) Bronchial effects of aerosolised D9-tetrahydrocannabinol in healthy and asthmatic subjects. American Review of Respiratory Disease 115, p57-

Williams SJ, Hartley JPR, & Graham JDP (1976) Bronchodilator effect of D1-tetrahydrocannabinol administered by aerosol of asthmatic patients. Thorax 31 p720

Abboud RT & Sanders HD (1976) Effect of oral administration of Delta9- Tetrahydrocannabinol on airway mechanics in normal and asthmatic subjects. Chest 70(4)

Graham JDP (1986) The bronchodilator action of cannabinoids. Ch in Mechoulam R (ed) Cannabinoids as Therapeutic Agents. Boca Raton: CRC Press

Nirenberg T, Celluci T, Liepman M, Swift R & Sirota D (1996) Cannabis versus other drug use amongst methadone maintenance patients Psychology of Addictive Behaviours Vol 10 No 4 pp222-227

Saxon A, Greenberg D, & Haver V (1993) Urine Screening for Marijuana Among Methadone Maintained Patients American Journal on Addictions Vol 2 No 3 pp207-11

Birch EA (1889) The use of Indian hemp in the treatment of chronic chloral and chronic opium poisoning The Lancet 1 p625 30-3-1889

Mattison JB (1891) Cannabis indica as an anodyne and hypnotic St Louis Medical & Surgical Journal 61 265-271

Burroughs W. (1953) Junky. London: Penguin p18

Mikuriya TH (1997) - personal communication 13-4-97

Haw S. (1985) Drug problems in greater Glasgow. London: SCODA

Haw S [1984] op cit., Atha (1987), 1996 op cit..

Chesher GB, Zaluzny SG, Jackson DM & Malor R . (1979) The attenuation by D9 THC and morphine of the quasi-morphine withdrawal syndrome in rats. Psychopharmacology 61 207-216

Chesher GB & Jackson DM (1985) Pharmacol. Biochem Behav. 23 pp13-15

Hirschorn ID & Rosencrans JA (1974) Psychopharmacology 36 pp243-253

Hine B, Friedman E. Torrelio M & Gershon S. (1975) Morphine-dependent rats: blockade of precipitated abstinence by D9 THC. Science 187 443-445.

Bhargava HN (1976) Inhibition of naloxone-induced withdrawal in morphine dependent mice by 1-trans D9 THC. European Journal of Pharmacology 36 259-262

Bhargava 1976, 1978, Frederickson et al 1976, Gilbert 1981, Jacob et al 1981, Lal et al 1981, Young et al 1981 - All cited by Pertwee RG [1991] Tolerance and dependence of psychotropic cannabinoids. Ch. in Pratt JA (Ed) 1991 - The biochemical basis of drug tolerance and dependence. London: Academic Press

Radouco-Thomas S, Magnan F & Radouco-Thomas C (1976) Phamacogenetic studies on cannabis and narcotics: Effects of D9 tetrahydrocannabinol and morphine in developing mice. Ch. in Nahas G (Ed) Marijuana: Chemistry, biochemistry, and cellular effects. New York: Springer-Verlag.

Pertwee RG (1992) In vivo interactions between psychotropic cannabinoids and other drugs involving central and peripheral neurochemical mediators. Ch in Murphy L & Bartke A (1992) Marijuana/Cannabinoids - neurobiology and neurophysiology

Matsuda LA, Lolait SJ, Brownstein MJ, Young AC & Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA Nature 346 pp561-564

Childers SR, Fleming L, Konkoy C, Marckel D, Pacheco M, Sexton T & Ward S (1992) Opioid and cannabinoid receptor inhibition of adenylyl cyclase in brain. Conference Proceedings - The Neuorobiology of drug and alcohol addiction. Eds Kalivas PW & Samson HH, Annals of the New York Academy of Sciences. USA:CCP

Cohen S (1989) The Chemical Brain - the neurochemistry of addictive disorders.

Gray's Anatomy (35th Ed) London: Longman 1973 p879.

Gold MS & Miller NS (1995) The neurobiology of drug and alcohol addictions In Miller & Gold (Eds) Pharmacological therapies for drug and alcohol addictions. New York, Marcel Dekker

V Navaratam & K Foong (1990) Adjunctive drug use amongst heroin addicts. Current Medical Research Opinion. Vol 11 No10 pp611-619

Jackson D (April 1997) Cannabis availability. Consequences of a perceived dearth in the market on heroin users Airedale Community Health Trust.

A. Saxon, D. Greenberg & V. Haver (1993) Urine screening for Marijuana among methadone maintained patients. American Journal on Addictions. Vol2 No 3 pp207-11

G. Tanda, F.E. Pontieri & G. Di Chiara (1997) Cannabinoid and Heroin Activation of Mesolimbic Dopamine Transmission by a Common µ1 Opioid Receptor Mechanism Science Volume 276 Number 5321 pp2048-2050

Editorial (1997) A Bad Case of Deja Vu.. New Scientist No 2089 p3

E.P. Nace, A.L. Mayers, F.M. Rothberg & F. Moleson (1975) Addicted and non addicted drug users. A comparison of drug usage patterns. Archives General Psychiatry. Vol 32 Pt 1 pp77-80

M.Lap & E. Drucker (1994) Recent changes in the Dutch cannabis trade; The case for regulated domestic production. International Journal of Drug Policy Vol 5 No 4

Adam 1996. The Amsterdam Drugs Policy. Information and Public Relations Department, City of Amsterdam. Http://www.drugtext.nl/drugtext/usa/count/nl/adam1.html

Mattison JB (1891) Cannabis Indica as an Anodyne & Hypnotic. St Louis Medical & Surgical Journal LVI (5) pp265-271

Reynolds JR (1890) Therapeutical uses and toxic effects of cannabis indica. The Lancet 1 pp637-638

Cited in Adams (1942) Marijuana. Bulletin of the New York Academy of Medicine 18 pp705-730 reprinted in Mikuriya (1973) op cit. p 369

Kaplan J (1970) Marijuana, the new prohibition. New York: World Publishing (Pocket Books 1971 Edition) pp306-308.

Cited in Commons D (1968) Marijuana & Alcohol p23 - cited Kaplan J (1970) op cit.

Tart CT & Klein CB (1969) Marijuana, Alcohol & Psychedelic (hallucinogen) use in student population p6 - cited Kaplan J (1970) op cit.

Halleck S (1968) Marijuana & LSD on campus p6 - cited Kaplan J (1970) op cit.

Downs G (1969) The use and abuse of marijuana and alcohol. Table 6 -cited Kaplan J (1970) op cit.

Mikuriya, T. H.(1970) Cannabis Substitution. An Adjunctive Therapeutic Tool in the Treatment of Alcoholism. Medical Times, 98 (4) pp187-191

Scher J (1971) Marijuana as an agent in rehabilitating alcoholics. American Journal of Psychiatry 127:7 pp147-148

Rosenberg CM, Gerrein JR & Schnell C (1978) Journal of studies on alcohol 39 (11) pp1955-1958

Jones RT & Stone GC (1970) Psychological studies of marijuana and alcohol in man. Psychopharmacologia 18 (1) pp108-117

Hollister (1979) op cit.

Thompson LJ & Proctor RC (1953) Pyrahexyl in the treatment of drug and alcoholic withdrawal symptoms North Carolina Medical Journal 14 (October 1953). p520-523

Brecher EM (1972) The Consumers Union Report on Licit and Illicit Drugs Chapter 58. Can marijuana replace alcohol?

Bello J (1996) The benefits of marijuana - physical, psychological & spiritual. Cottonwood CA: Sweetlight pp86-88

Hoffman PL, Grant KA, Snell LD Reinlib L & Iorio K (1992) The Neurobiology of drug and alcohol addiction. Annals of the New York Academy of Sciences 654 pp52-60

(+)-HU-210

Feigenbaum et al (1989) Nonpsychotropic cannabinoid acts as functional NMDA blocker Proc Nat Acad Sci USA 86 p 9584. Cited in Consroe P & Sandyk R (1992)

Consroe P & Sandyk R (1992) Potential role of cannabinoids for therapy of neurological disorders - Ch. in Marijuana/Cannabinoids. Neurobiology & Neurophysiology. (Murphy & Bartke eds), CRC Boca Raton

Hammer T & Vaglum P (1990) Initiation, continuation and discontinuation of cannabis use in the general population. British Journal of Addiction 85 p 899-909

Novel analysis of survey data from Atha & Blanchard (1997) op cit. - summary tables available on request.

Alcohol Concern (1996) Factsheet

General Household Survey 1996-97, reported in Social Trends 28 table 7.18. Office for National Statistics 1998 (figures in table estimated from graphical representations)

 

Mikuriya T, cited in Cermack T L (1997) CSAM Cannabis White Paper CSAM Task Force on Medical Marijuana

California Department of Justice Information Bulletin No. 97-BNE-01, 24th February 1997: Peace Officer Guide, Compassionate Use Act 1996

City & County of San Francisco Department of Public Health; Memo to District Attorney, 12th February 1997: Final documents & guidelines for the implementation of Prop 215.

San Francisco Examiner 9 June 1998

Aitken D & Mikuriya TH (1980) The Forgotten Medicine. The Ecologist 10 (8/9/80) pp269- 279

Feldman HW & Mandel RJ (1998) Providing Medical Marijuana: The importance of Cannabis Clubs. Journal of Psychoactive Drugs 30 (2) April-June 1998 pp 179-186

San Francisco Chronicle 27 May 1998, San Francisco Examiner Fri, 29 May 1998

Jury Clears Man Who Used Cannabis As Pain Killer The Guardian (Saturday 6th June 1998)

Patient grew cannabis after hospital tests The Daily Telegraph (Friday 30th May 1997)/Electronic Telegraph Issue 735

Church Discusses 'Harmless Drug But The Arrests Go On The Independent on Sunday (Sunday 14th June 1998)

Pot-Growing Transplant Man Is Freed The Times (Tuesday 24th March 1998)